TY - JOUR
T1 - Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease
AU - Ahluwalia, Namanjeet
AU - Blacher, Jacques
AU - Szabo de Edelenyi, Fabien
AU - Faure, Patrice
AU - Julia, Chantal
AU - Hercberg, Serge
AU - Galan, Pilar
N1 - Funding Information:
The SU.FOL.OM3 trial was supported by the French Ministry of Research [ R02010JJ ]; Ministry of Health (DGS) ; Sodexo; Candia; Unilever; Danone; Roche Laboratory; Merck EPROVA GS; and Pierre Fabre Laboratory. The funding agencies were not involved in study design, analysis, and interpretation.
PY - 2013/6
Y1 - 2013/6
N2 - Background: Few studies have examined simultaneously the prognostic value of traditional and emerging biomarkers including atrial natriuretic peptide (ANP) and brain-type natriuretic peptide (BNP), for major cardiovascular disease (CVD) outcomes in patients with stable CVD, and results are equivocal. Design: and Methods: Mid-regional pro-ANP (MR-proANP) and N-Terminal pro-BNP (NT-proBNP), CRP and homocysteine were measured in stable CVD patients (n=1456; age: 61.8y) at inclusion in the SU.FOL.OM3 cohort. Prospective association of biomarkers with risk of heart failure, major cardiovascular (non-fatal myocardial infarction, ischemic stroke or death from CVD) or overall cardiovascular event were examined with Cox proportional-hazards analyses. Increase in prediction risk upon addition of biomarker(s) to the traditional risk model was examined by change in C-statistic, NRI and IDI. Results: During follow-up (median: 4.7y), 40 heart failure, 145 major cardiovascular and 493 overall cardiovascular events were diagnosed. In models adjusted for age, sex, smoking, diabetes, serum creatinine and CVD inclusion criteria, NT-proBNP and CRP associated significantly with heart failure. Both natriuretic peptides predicted the risk of major cardiovascular events in adjusted models; Hazard ratio(HR) and 95% CI for each SD increase in MR-proANP and NT-proBNP were 1.24 (1.04-1.47), and 1.31 (1.09-1.57), respectively. The addition of NT-proBNP to a traditional risk model increased significantly the area-under-curve for heart failure and overall cardiovascular events (by 6 and 12%, respectively); addition of MR-proANP or homocysteine yielded modest (2%) but statistically significant increase for major cardiovascular events. Conclusion: NT-proBNP consistently predicted CVD outcomes and may be useful singly or in combination with MR-proANP for risk-stratification in high-risk patients.
AB - Background: Few studies have examined simultaneously the prognostic value of traditional and emerging biomarkers including atrial natriuretic peptide (ANP) and brain-type natriuretic peptide (BNP), for major cardiovascular disease (CVD) outcomes in patients with stable CVD, and results are equivocal. Design: and Methods: Mid-regional pro-ANP (MR-proANP) and N-Terminal pro-BNP (NT-proBNP), CRP and homocysteine were measured in stable CVD patients (n=1456; age: 61.8y) at inclusion in the SU.FOL.OM3 cohort. Prospective association of biomarkers with risk of heart failure, major cardiovascular (non-fatal myocardial infarction, ischemic stroke or death from CVD) or overall cardiovascular event were examined with Cox proportional-hazards analyses. Increase in prediction risk upon addition of biomarker(s) to the traditional risk model was examined by change in C-statistic, NRI and IDI. Results: During follow-up (median: 4.7y), 40 heart failure, 145 major cardiovascular and 493 overall cardiovascular events were diagnosed. In models adjusted for age, sex, smoking, diabetes, serum creatinine and CVD inclusion criteria, NT-proBNP and CRP associated significantly with heart failure. Both natriuretic peptides predicted the risk of major cardiovascular events in adjusted models; Hazard ratio(HR) and 95% CI for each SD increase in MR-proANP and NT-proBNP were 1.24 (1.04-1.47), and 1.31 (1.09-1.57), respectively. The addition of NT-proBNP to a traditional risk model increased significantly the area-under-curve for heart failure and overall cardiovascular events (by 6 and 12%, respectively); addition of MR-proANP or homocysteine yielded modest (2%) but statistically significant increase for major cardiovascular events. Conclusion: NT-proBNP consistently predicted CVD outcomes and may be useful singly or in combination with MR-proANP for risk-stratification in high-risk patients.
UR - http://www.scopus.com/inward/record.url?scp=84878114762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878114762&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2013.03.017
DO - 10.1016/j.atherosclerosis.2013.03.017
M3 - Article
C2 - 23582589
AN - SCOPUS:84878114762
VL - 228
SP - 478
EP - 484
JO - Atherosclerosis
JF - Atherosclerosis
SN - 0021-9150
IS - 2
ER -